

NASS VALLEY GATEWAY LTD.

Form 51-102F1

**Management's Discussion and Analysis of Financial Results For
the nine months ended September 30, 2020**

Containing information up to and including November 30, 2020

This Management Discussion and Analysis ("MD&A") is intended to help the reader understand the financial statements of Nass Valley Gateway Ltd. ("Nass Valley" or the "Company"). The information herein should be read in conjunction with the financial statements for the nine months ended September 30, 2020 and 2019. The financial statements for the nine months ended September 30, 2020 have been prepared in accordance with International Financial Reporting Standards ("IFRS"). The following discussion may contain management estimates of anticipated future trends, activities or results. These are not a guarantee of future performance, since actual results could change based on factors and variables beyond management control. All monetary amounts are in Canadian dollars unless otherwise stated.

This MD&A is the responsibility of management. The Board of Directors carries out its responsibility for the review of this disclosure directly and through its audit committee comprised primarily of independent directors. The audit committee reviews and approves this disclosure prior to its publication, pursuant to the authority delegated to it by the Board of Directors.

The reader is encouraged to review the Company's statutory filings on www.sedar.com ("Sedar") and to review general information.

Description of Business and Overall Performance

The Company was incorporated on October 25, 2005 under the British Columbia Business Corporation Act. The Company became a reporting issuer on February 26, 2007 and the common shares of the Company were listed on the Canadian Securities Exchange ("CSE") on March 9, 2007 under the trading symbol 'NVGL', which was changed in September 2008 to "NVG". Since October 5, 2007, the Company's common shares have been co-listed on the "Open Market" of the Frankfurt (Germany) Stock Exchange and are trading under the symbol "3NVN". The Company's common shares are also traded on the Third Market Segment called Freiverkehr on the Berlin and Bremen Stock Exchange.

As at June 30, 2019 the Company owns two wholly owned subsidiaries, Pro-Thotics Technology Inc ("PTI") and Advanced Bioceuticals Limited ("ABL") which were acquired in a reversed takeover ("RTO") on March 18, 2019.

Pro-Thotics Technology Inc ("PTI") was incorporated in September 1988 in the State of New York and has been a Durable Medical Equipment Supplier ("DME") since inception. On April 3, 2016 Global1 Solutions LLC and National Brace Inc. purchased 100% of PTI, expanding the business into a national marketer of off the shelf Orthotics to a broad base of patients based throughout the United States.

PTI at that time had offices in Patchogue, New York and Tamarac, Florida. The main business was that of custom fit orthotics, with patients generated by salesman and hospitals. The Company also sold arterial compression devices, lymphedema pumps and prosthetics.

Subsequently to taking over in 2016, the new management decided to change the business model from custom fit to drop ship / mail order model. The sales of the compression devices, lymphedema pumps and prosthetics were phased out. In addition the Company also stopped 3rd party billing. This resulted in revenues declining from 2016 to 2017.

During 2017 and 2018 sales steadily improved and continued into 2019.

During Q2 2019 revenue was negatively affected by the contraction in the DME industry because of US government policy. PTI subsequently ceased operations shortly thereafter. At September 30, 2020, the assets and liabilities of PTI are reported as held for sale. The Company is still in discussions with potential buyers.

ABL was incorporated on January 31, 2018 in the State of New Jersey and on February 1, 2018 acquired 100% of PTI. Global1 Solutions LLC and National Brace Inc each became a 50% shareholder of ABL in an exchange of equity of a company under common control.

NASS VALLEY GATEWAY LTD.

Form 51-102F1

Management's Discussion and Analysis of Financial Results For

the nine months ended September 30, 2020

Containing information up to and including November 30, 2020

On March 22, 2018 the Company entered into a Definitive Acquisition and Share Exchange Agreement whereby Nass Valley Gateway Ltd acquires a 100% interest in Advanced Bioceuticals Limited and its wholly owned subsidiary Pro-Thotics Technologies Inc. in exchange for 89.27% of the common shares of the Nass Valley Gateway Ltd. Since ABL's shareholders own a majority of the common shares of the Company subsequent to the CSE approval, the proposed transaction together with the recapitalization, was considered as a reverse takeover ("RTO").

On March 4, 2019 the Company announced that following an internal Listing Application Review, the CSE had approved the fundamental change of Nass Valley Gateway Ltd. for listing subject to the following conditions:

- 1) Completion of the acquisition (the "Acquisition") of Advanced Bioceuticals Limited ("ABL");
- 2) Completion of any and all outstanding CSE application documentation and payment of fees pursuant to the Policies of the CSE.

On March 13, 2019 the parties amended the DASE-Agr by changing the consideration for the 100% ownership interest of ABL and including ABL's wholly owned subsidiary Pro-Thotics Technology, Inc. from 400,000,000 common shares of NVG at a deemed price of \$0.10 per share to 280,000,000 common shares of NVG at a deemed price of \$0.1429 per share representing 89.7% of the Company's issued common shares (85.06% on a fully diluted basis).

On March 18, 2019, the Company issued 280,000,000 common shares as total consideration for its acquisition of Advanced Bioceuticals Limited ("ABL") and Pro-Thotics Technology Inc. ("PTI") as wholly owned subsidiaries. The total number of the issued and outstanding common shares of the Company increased to 312,143,477.

The 280,000,000 issued common shares are subject to the four months hold period pursuant to the Canadian securities laws, of which 266,000,000 common shares are also subject to resale restrictions prescribed by the U.S. securities laws and cannot be resold during the next 12 months and without strict compliance with the U.S. securities laws. 261,400,000 common shares of the issued 280,000,000 common shares are also subject to an escrow agreement, a copy of which is available under the profile of the Company on www.sedar.com.

As wholly owned subsidiaries of Nass Valley, ABL will continue to focus on commencing the sale of hemp based cannabidiol (CBD) with zero Tetrahydrocannabinol (THC) content products including CBD infused skin, bath, and body care products (the "ABL-Business") and PTI will continue to focus on expanding the sale of Durable Medical Equipment ("DME" or "PTI-Business").

On March 25, 2019 Nass Valley's Board of Directors announced its approval of the appointment of two Directors and Officers pursuant to its fundamental acquisition.

Mr. John Affenita was appointed as a Director, President and the Chief Executive Officer ("CEO") of Nass Valley. Mr. Affenita is also the CEO of Nass Valley's acquired subsidiary Pro-Thotics Technology Inc, a position he has held since 2000. Mr. Affenita is the founder of Pro-Thotics Technology, Inc. He is an ABC (American Board of Certification) Orthotist and Prosthetist ("O&P") member, serving the O&P field for 20 years. He has since resigned as CEO.

Mr. Darren Palestine was appointed May 30, 2019. He is an experienced professional with twelve years of operational management, business development, sales management, and underwriting experience in asset-based lending. He is the Owner and Operator of a Lending and Consulting Firm and is a focused leader with success in both inbound and outbound sales, networking, and business development. Mr. Palestine has multiple articles and interviews published in various Industry publications, is a featured panelist on Alternative Financing Panels.

Mr. Michal Semler was appointed as the Chief Financial Officer of Nass Valley. Mr. Semler has been in the healthcare and wellness business for the last 10 years. He also was instrumental in capital fundraising for Pro-Thotics Technologies and its affiliates and maintains all financial relationships with banking, private equity, and investor partners.

On March 29, 2019 the shares of Nass Valley Gateway resumed trading.

NASS VALLEY GATEWAY LTD.

Form 51-102F1

**Management's Discussion and Analysis of Financial Results For
the nine months ended September 30, 2020**

Containing information up to and including November 30, 2020

On May 6, 2019 the Company announced that it signed a letter of intent ("LOI") with CSB Supply BV ("CSB"). CSB is a global business to business wholesale supplier of CBD (Cannabidiol) products located in The Netherlands and under the terms of the LOI will supply and the company will market and distribute CBD products nationally in the United States and Canada under the Nass Valley brand.

On June 7th, 2019, Michael Semler (CFO) and Armand Assante were elected to the Board of Directors.

On July 26, 2019, the Company informed CSB it would terminate the proposed LOI per the agreement.

On August 26th, 2019, the Company entered into a definitive JV (joint venture) agreement with Dynamic Blending Specialists (DBS), a contract manufacturer of cosmetic and dermatological products located in Vineyard, Utah, USA. DBS will, under the terms of the agreement, provide the Company with zero-THC CBD products for the period of one year. The JV can be extended by mutual agreement between DBS and

the Company. Also, DBS executives Gavin Collier will serve as CEO of the Company and Jordan Erskine will serve as COO of the Company, Mr. Erskine will also serve as Director and on the audit committee. Each will be under Company employee contracts and each will be granted 1M shares of Company common shares. Mr. Affenita resigned as CEO and stayed on as a consultant to PTI.

On November 8th, 2019, the Company ordered its first 20k units of CBD products from DBS under the Nass Valley Gardens brand name.

On November 14th, 2019, the Company hired Todd Sonaga, a public and investor relations consultant to run all of the Company's investor relations and communications.

On December 19th, 2020, the Company retained the services of Gil Ventures, a Miami Florida-based digital marketing and advertising agency to lead digital marketing strategy, product innovation, and packaging design.

On February 19th, 2020, the Company began testing e-commerce strategies utilizing social media platforms.

In March, 2020, the Coronavirus essentially shutdown all formerly normal business practices and activities. Consumer shopping habits drastically changed as the economy faced unprecedented challenges and uncertainty which resulted in massive closures, historic unemployment and subsequently forcing government subsidies to individuals and businesses alike. The Company stopped all e-commerce marketing and social media marketing to protect against spending high-risk capital while it waits for the economy to return to activity. The company is poised and expects to start selling its CBD products into its sales channels again in Q4 2020.

On July 16th, NVG filed its 2019 EOY audited financials and MD&A per the 30-day extension granted by the BCSC.

On September 2nd, 2020, NVG announced it was offering a new line of products and new packaging designs to go along with an overall branding redesign.

On September 16th, 2020, NVG announced its new revenue-sharing partnership with New Hope Labs, located in Miami, Florida, and who will produce a new line of human and pet hemp-based products under the Nass Valley Gardens brand. New Hope Labs will provide NVG access to all-natural seed products, extraction facilities, packaging and product fulfillment, allowing NVG to enter into new markets while building towards its goal of being a fully-integrated hemp products company.

On October 15th, 2020, NVG announced it was entering the pet market as management had been pursuing additional consumer audiences and found data to support the strategy of cross-selling into households that own pets.

On November 11th, 2020, NVG announced a new marketing partnership with digital agency Branded Book who specialize in the healthcare and wellness markets.

Future Developments

The Company is fully committed to producing and marketing CBD consumer products marketed under the brand name of Nass Valley Gardens. There are plans to expand the Company's sales channels beyond ecommerce, social media, and retail. There are also plans to potentially enter into new products such as food products that are hemp-based.

The Company continues to focus on selling its remaining PTI assets. It plans to divest of PTI because of the change in market conditions stated earlier and is in negotiations with a potential buyer. While a buyer has been identified, there is no certainty that this buyer will complete the purchase.

FINANCING

During the nine months ended September 30, 2020, and following the discontinuance of the PTI operations, the Company used financing from related parties for operations and development of its new CBD business. The Company anticipates that it will continue to receive financing from related parties to further establish and expand its CBD offering but projects cash flow from CBD products sales revenue will fully finance its operational expenses by end Q4 2020.

On March 3, 2019, the Company received an additional \$12,763 to the previously received funds for the exercise of 256,000 share purchase warrants at \$0.10 per share.

On March 28, 2019, the Company received \$26,000 for the exercise of 260,000 stock options at \$0.10 per share.

On April 10, 2019, the Company received \$2,000 for the exercise of 20,000 stock options at \$0.10 per share.

On April 10, 2019, the Company granted 1,555,000 new incentive stock options to its Directors, Officers and consultants at a price of \$0.18 per share and an expiry date of April 10, 2022.

On May 26, 2019, 240,000 stock options which the Company had granted on April 10, 2019 were cancelled due to the resignation of one Director.

On July 19, 2019, the Company converted \$15,330 from an AP to a management company for services rendered into payment for the exercise of 153,300 share purchase warrants.

Highlights and Subsequent Events

There have been no significant events subsequent to September 30, 2020.

On August 26th, 2019, the Company entered into a definitive JV (joint venture) agreement with Dynamic Blending Specialists (DBS), a contract manufacturer of cosmetic and dermatological products located in Vineyard, Utah, USA. DBS will, under the terms of the agreement, provide the Company with zero-THC CBD products for the period of one year. The JV can be extended by mutual agreement between DBS and the Company. Also, DBS executives Gavin Collier will serve as CEO of the Company and Jordan Erskine will serve as COO of the Company, Mr. Erskine will also serve as Director and on the audit committee. Each will be under Company employee contracts and each will be granted 1M shares of Company common shares. On January 17th, 2020 Mr. Michael Racaniello was invited by the BoD and accepted to serve as a Director of Nass Valley Gateway Ltd. Mr. Racaniello is a member of the majority shareholder group.

The novel coronavirus, and its dramatic negative effects on society as a whole and the business world, forced management to cease marketing its existing portfolio of Nass Valley Gardens branded Isolate CBD

NASS VALLEY GATEWAY LTD.

Form 51-102F1

**Management's Discussion and Analysis of Financial Results For
the nine months ended September 30, 2020****Containing information up to and including November 30, 2020**

products. In Q4 2020, the Company started to market its new line of high quality, full spectrum hemp products on e-commerce and in other sales channels.

Results of Operations**The nine months ended September 30, 2020 compared to the nine months ended September 30, 2019**

Net loss and comprehensive loss for the nine months ended September 30, 2020 amounted to \$556,903 (loss per share - \$0.00) compared to a loss of \$485,050 (loss per share - \$0.00) in the nine months ended September 30, 2019.

Revenue for the nine months ended September 30, 2020 was \$nil compared to revenue for the nine months ended September 30, 2019 amounted to \$560,543 reported from PTI. The revenue and expenses from PTI for the nine months ended September 30, 2019 was reported as discontinued operations, net loss amounting to \$141,378.

The decrease in loss was mainly due to:

- (i) a decrease of \$560,543 in revenue from \$560,543 in 2019 to \$nil in 2020 due to decreased sales in PTI and overall transition of the business from orthotics-based to CBD- based;
- (ii) a decrease of \$21,799 in marketing and promotion expenses from \$140,722 in 2019 to \$118,923 in 2020;
- (iii) an increase in professional fees of \$267,500 from \$57,217 in 2019 to \$324,717 in 2020, professional fees in 2019 for PTI was reported as discontinued operations;
- (iv) an increase of \$80,755 in office and miscellaneous from \$24,699 in 2019 to \$105,454 in 2020.
- (v) a decrease in share based compensation of \$118,033 from \$118,033 in 2019 to \$nil in 2020 due to the grant of new stock options.

Selected annual information

	Years Ended December 31		
	2019 (audited)	2018 (audited)	2017 (audited)
	\$	\$	\$
Total revenues	nil	nil	nil
General and administrative	663,950	89,650	111,604
Loss for the year-continuing operations	(2,158,192)	(96,126)	(111,604)
Loss for the year-discontinued operations	(1,146,682)	(2,068,885)	nil
Loss per share – basic and diluted (continuing operations)	(0.01)	(0.00)	(0.01)
Total assets	552,993	1,000,810	108,131
Total long –term liabilities	-	-	-
Shareholders' equity	(5,167,352)	(3,823,024)	107,517
Cash dividends declared - per share	-	-	-

NASS VALLEY GATEWAY LTD.

Form 51-102F1

Management's Discussion and Analysis of Financial Results For**the nine months ended September 30, 2020****Containing information up to and including November 30, 2020****Selected quarterly information ⁽¹⁾**

Three months ended	Sep 30, 2020	June 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	June 30, 2019
Total assets	1,260,355	562,152	695,315	552,993	1,504,124	1,507,259
Working capital (Deficiency)	(988,837)	(744,404)	(814,143)	(477,275)	(1,777,666)	(1,756,737)
Shareholders' equity	(5,702,118)	(5,562,044)	(5,664,153)	(5,167,352)	(1,777,666)	(1,756,737)
Revenue	nil	nil	nil	nil	nil	560,543
Net income (loss)	(254,535)	(113,562)	(188,806)		(11,112)	(473,939)
Earnings (loss) per share	0.00	0.00	0.00	0.00	0.00	0.00

(1) Before the RTO ABL was a privately held company and as such was not required to file interim financial statements. Only the last five quarters are available.

Liquidity

The Company's working capital and deficit positions at September 30, 2020 and December 31, 2019 were as follows:

	September 30 2020 (unaudited)	December 31 2019 (audited)
Working capital	\$ (988,837)	\$ (477,275)
Deficit	\$ (7,502,286)	\$ (6,945,383)

The cash positions at September 30, 2020 and December 31, 2019 were \$370,578 and \$18,317 respectively.

The Company is dependent on funding from related parties for operations.

While the Company will seek to maximize recoveries and reduce operating costs, estimates and assumptions influencing these parameters may prove incorrect. Incorrect assumptions may result in material differences between estimated and actual results. The Company has no way of predicting the future price and the ability to sell the developed products. As a result, revenue derived from future operations, if any, will be impacted.

The Company has historically relied upon equity financings and loans from related parties to satisfy its capital requirements and will continue to depend heavily upon equity capital to finance its activities in spite of alternative financial instrument available to the Company.

There can be no assurance the Company will be able to obtain required financing in the future on acceptable terms. The Company anticipates the need of additional capital in the future to finance its ongoing operations and development, such capital to be derived from the exercise of outstanding stock options, share purchase warrants, the completion of other equity financings and/or possible issuance of corporate bonds of convertible debentures. The Company has presently limited financial resources, no

NASS VALLEY GATEWAY LTD.**Form 51-102F1****Management's Discussion and Analysis of Financial Results For****the nine months ended September 30, 2020****Containing information up to and including November 30, 2020**

assurance that additional funding will be available to it to augment the future development of its projects, although the Company has been successful in financing its activities through the sale of equity securities in the past. The ability of the Company to arrange additional financing in the future will depend, in part, on the prevailing capital market conditions.

In recent months, the global securities markets have experienced high volatility in price and volume and companies, particularly in the life science sector, which have not necessarily been related to the operating performance, underlying asset values or prospects of such companies. There can be no assurance that continual fluctuations in the Company's share prices will not occur, or that these fluctuations will not affect the ability of the Company to raise equity funding, and if at all, without causing a significant dilution to its existing shareholders. Any quoted market for the common shares may be subject to market trends generally, notwithstanding any potential success of the Company in creating revenue, cash flows or earnings.

Capital Resources

At September 30, 2020 the Company had a share capital of \$1,329,274 (December 31, 2019: \$1,329,274), representing 312,832,777 (December 31, 2019: 312,832,777) common shares without par value, and an accumulated deficit of \$7,502,286 (December 31, 2019: \$6,945,383). The shareholders' equity amounted to \$(5,702,118) (December 31, 2019: \$(5,167,352)).

Additional Disclosure for Venture Issuers

Additional disclosure concerning the Company's general and administrative expenses is provided in the Company's Statement of Operations, Comprehensive Loss and Deficit included in its financial statements for the nine months ended September 30, 2020 and 2019 which are available on SEDAR at www.Sedar.com.

Related Party Transactions**Key Management personnel compensation**

Key management personnel include the Company's executive officers and Board of Director members. Key management compensation consists of the following for the nine months ended September 30, 2020 and the year ended December 31, 2019:

	Sep 30, 2020 (unaudited)	December 31, 2019 (audited)
Gregory Vax, Director of PTI and ABL	\$ -	\$ 59,711
Michael Racaniello, Director of PTI and ABL	-	59,711
Share based compensation for Directors and Officers	-	234,905
Total	-	354,327

During the nine months ended September 30, 2020 the Company entered into the following transactions with related parties.

The amounts due to/from related parties were as follows:

	Sep 30, 2020 (unaudited)
--	--------------------------------

NASS VALLEY GATEWAY LTD.**Form 51-102F1****Management's Discussion and Analysis of Financial Results For****the nine months ended September 30, 2020****Containing information up to and including November 30, 2020**

	\$
Due from related parties:	
Greg Vax	74,031
Michael Racaniello	46,687
National Brace	90,265
MMVX LLC	308,804
MHI	47,523
KPM	23,386
	<hr/> 590,696 <hr/>
Due to related parties:	
Global 1	178,285
ARD Ventures	53,355
Linear Consulting	166,738
National Brace	26,135
	<hr/> 424,513 <hr/>

These transactions are in the normal course of operations and, in management's opinion, are undertaken with the same terms and conditions as transactions with unrelated parties. Accordingly, these transactions are measured at exchange amounts, which are the amounts of consideration negotiated, established and agreed to by the related parties.

Advances from related party

The amounts due from related parties are non-interest bearing, unsecured and on long term basis.

Off Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements.

Directors and Officers

Gavin Collier	Chief Executive Officer, President and Director, appointed August 26th, 2019
Michael Semler	Chief Financial Officer, appointed March 25, 2019, Director, appointed June 7th, 2019
Armand Asante	Director, appointed June 7th, 2019
Darren Palestine	Director, appointed May 30, 2019
Jordan Erskine	Chief Operating Officer, appointed Aug.26th, 2019, Director, Appointed Aug.26th, 2019
Michael Racaniello	Director, appointed January 17th, 2020

Outstanding Share Data as at November 30, 2020

NASS VALLEY GATEWAY LTD.**Form 51-102F1****Management's Discussion and Analysis of Financial Results For****the nine months ended September 30, 2020****Containing information up to and including November 30, 2020**

	Number outstanding	Exercise Price	Expiry Date
Common shares	312,832,777		
Common shares issuable on exercise:			
Stock options	100,000	\$0.10	December 5, 2020
Stock options	835,000	\$0.18	April 10, 2022
Warrants	3,500,000 ⁽¹⁾	\$0.11	October 16, 2020

(1) On September 19, 2016 the Board of Directors approved the amendment of these warrants to \$0.11 per share with an expiry date of October 16, 2020. This has since expired

Risks and Uncertainties

An investment in the securities of Nass Valley as a junior Company is speculative and subject to risks and uncertainties.

The following are some of the key risks and uncertainties identified; however, there may be other risks and uncertainties that have not been listed:

- Costs related to disclosure requirements are a financial burden for a company presently depending on equity funding for its working capital.
- An increase in competition to any new project the company may acquire.
- No assurance about the economic viability of any project the Company may acquire.
- Additional costs may be incurred, such as availability of experts related to the acquisition, development and marketing, especially of potential new generation of products.
- Additional expenditures will be required to establish permits and patents.
- There can be no assurance that a developed business plan will succeed in whole or in part.
- There are various government and environmental regulations that must be followed by the Company, which are changing constantly for most production projects.

The reader is encouraged to review the Company's 2A Listing Statement on www.sedar.com ("Sedar") which describes in detail all risk factors.

Critical Accounting Estimates

The preparation of the Company's financial statements requires management to use estimates and assumptions that affect the reported amounts of assets and liabilities as well as expenses.

(i) *Stock Based Compensation*

The Company uses Black-Scholes option pricing model to determine the fair value of awards for stock options granted to employees, officer, directors and consultants. These estimates are based on historical information and accordingly cannot be relied upon to predict the future behavior. These estimates are set out in notes to the annual financial statements.

(ii) *Financial Instruments*

The carrying values of the financial instruments have been estimated to approximate their respective fair values.

(iii) *Income Taxes*

The provision of income taxes is based on judgements in applying income tax law and estimates about timing, likelihood and reversal of temporary differences between accounting and tax basis of the assets and liabilities

(iv) *Going concern*

Management makes an assessment about the Company's ability to continue as a going concern by taking into the account the consideration of the various factors. Judgement is applied by management in determining whether or not the elements giving rise to factors that cause doubt about the ability of the Company to continue as a going concern are present.

Financial Instruments

The Company's financial instruments consisted of cash, loans mostly from related parties, amounts receivable from related parties, amounts payable, amounts payable to related parties and loans payable to related parties. This may change in future as the company is contemplating alternative financial instruments, like corporate bonds and/or convertible debentures. Unless otherwise noted, it is management's opinion that the Company is presently not exposed to significant interest, currency or credit risks arising from these financial instruments.

Credit risk

The Company is not exposed to significant credit risk, being in the development stage. Amounts receivable from related parties and amounts due to related parties are described in Note 8 to the financial statements.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its obligations associated with its financial liabilities. The Company has historically relied upon equity financings to satisfy its capital requirements and will continue to depend heavily upon equity capital to finance its activities. Although the executed transaction will drastically improve the cash flow of the Company, there can be no assurance the Company will be able to obtain required financing in the future on acceptable terms. The Company anticipates the need of additional capital in the future to finance ongoing development of its augmented technology, such capital to be derived from the exercise of outstanding stock options, warrants and/or the completion of other equity financings and the additional income from its substantial acquisition. Presently the Company still has limited financial resources and there is no assurance that additional funding will be available to it for future development of its projects, although the Company has been successful in the past in funding its activities through the sale of equity securities.

The ability of the Company to arrange additional financing besides its cash flow from its present operations will depend, in part, on the prevailing capital market conditions. The global securities markets have experienced wide fluctuations in prices which have not necessarily been related to the operating performance, underlying asset values or prospects of such companies. There can be no assurance that continual fluctuations in price will not occur. Any quoted market for the common shares may be subject to market trends generally, notwithstanding any potential success of the Company in creating revenue, cash flows or earnings.

Changes in Accounting Policies

The Company did not adopt any new or amended accounting standards during the year ended December 31, 2019 which had a significant impact on the Financial Statements.

New accounting standards effective for annual periods beginning on or after January 1, 2020:

IFRS 3, Business Combinations ("IFRS 3")

Amendments to IFRS 3, issued in October 2018, provide clarification on the definition of a business. The amendments permit a simplified assessment to determine whether a transaction should be accounted for as a business combination or as an asset acquisition.

The amendments are effective for transactions for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after January 1, 2020. The adoption of the amendments had no impact on the Company's unaudited condensed interim consolidated financial statements.

IAS 1, Presentation of Financial Statements ("IAS 1")

Amendments to IAS 1, issued in October 2018, provide clarification on the definition of material and how it should be applied. The amendments also align the definition of material across IFRS and other publications. The amendments are effective for annual periods beginning on or after January 1, 2020 and are required to be applied prospectively. The adoption of the amendments had no impact on the Company's unaudited condensed interim consolidated financial statements.

IAS 8, Accounting Policies, Changes in Accounting Estimates and Errors ("IAS 8")

Amendments to IAS 8, issued in October 2018, provide clarification on the definition of material and how it should be applied. The amendments also align the definition of material across IFRS and other publications.

The amendments are effective for annual periods beginning on or after January 1, 2020 and are required to be applied prospectively. The adoption of the amendments had no impact on the Company's unaudited condensed interim consolidated financial statements

Forward-Looking Statements

The statements made in this MD&A that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address the Company's expectations, should be considered forward-looking statements. Certain forward-looking information should also be considered future-oriented financial information ("FOFI") as that term is defined in NI 51-102. The purpose of disclosing FOFI is to provide a general overview of management's expectations regarding the anticipated results of operations and capital expenditures. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. Forward-looking statements are statements about the future and are inherently uncertain, and actual achievements of the Company and its subsidiaries may differ materially from those reflected in the forward-looking statements due to a variety of risks, uncertainties and other factors.

The Company's forward-looking statements are based on the beliefs, expectations and opinions of management on the date the statements are made, and the Company does not assume any obligation to update forward-looking statements if circumstances or management's beliefs, expectations or opinions should change except as required by law. You should not place undue reliance on these forward-looking statements. These statements reflect our current view of future events and are subject to certain risks and uncertainties as contained in the Company's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, our actual results could differ materially from those anticipated in these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events.

Although we believe that our expectations are based on reasonable assumptions, we can give no assurance that our expectations will materialize. The forward-looking statements made in this MD&A describe our expectations as at November 30, 2020.

"Gavin Collier"

On behalf of the Board
Gavin Collier
Chief Executive Officer